DK1051187T3 - Behandling af follikulære lymfomer ved anvendelse af inhibitorer af lymfotoxin(LT)-syntesevejen - Google Patents

Behandling af follikulære lymfomer ved anvendelse af inhibitorer af lymfotoxin(LT)-syntesevejen

Info

Publication number
DK1051187T3
DK1051187T3 DK99903480T DK99903480T DK1051187T3 DK 1051187 T3 DK1051187 T3 DK 1051187T3 DK 99903480 T DK99903480 T DK 99903480T DK 99903480 T DK99903480 T DK 99903480T DK 1051187 T3 DK1051187 T3 DK 1051187T3
Authority
DK
Denmark
Prior art keywords
inhibitors
lymphotoxin
pathway
treatment
follicular lymphomas
Prior art date
Application number
DK99903480T
Other languages
Danish (da)
English (en)
Inventor
Jeffrey Browning
Jeanette Thorbecke
Vincent Tsiagbe
Original Assignee
Univ New York
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York, Biogen Inc filed Critical Univ New York
Application granted granted Critical
Publication of DK1051187T3 publication Critical patent/DK1051187T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C07K14/5255—Lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK99903480T 1998-01-30 1999-01-29 Behandling af follikulære lymfomer ved anvendelse af inhibitorer af lymfotoxin(LT)-syntesevejen DK1051187T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7311298P 1998-01-30 1998-01-30
US7341098P 1998-02-02 1998-02-02
PCT/US1999/001928 WO1999038525A1 (en) 1998-01-30 1999-01-29 Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway

Publications (1)

Publication Number Publication Date
DK1051187T3 true DK1051187T3 (da) 2004-03-08

Family

ID=26754147

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99903480T DK1051187T3 (da) 1998-01-30 1999-01-29 Behandling af follikulære lymfomer ved anvendelse af inhibitorer af lymfotoxin(LT)-syntesevejen

Country Status (24)

Country Link
EP (1) EP1051187B9 (de)
JP (2) JP4713733B2 (de)
KR (1) KR100622960B1 (de)
CN (1) CN1287853C (de)
AT (1) ATE253930T1 (de)
AU (1) AU752710B2 (de)
BR (1) BR9908214A (de)
CA (1) CA2319698A1 (de)
CZ (1) CZ301026B6 (de)
DE (1) DE69912743T2 (de)
DK (1) DK1051187T3 (de)
EA (1) EA003862B1 (de)
EE (1) EE05235B1 (de)
ES (1) ES2211035T3 (de)
HU (1) HU226044B1 (de)
IL (2) IL137489A0 (de)
IS (1) IS2254B (de)
NO (1) NO328116B1 (de)
NZ (1) NZ506529A (de)
PL (1) PL203279B1 (de)
PT (1) PT1051187E (de)
SK (1) SK285725B6 (de)
TR (2) TR200002203T2 (de)
WO (1) WO1999038525A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1047045A1 (zh) * 1999-06-28 2003-02-07 Abbott Gmbh & Co. Kg 預防腫瘤生長的方法
EP1263788A2 (de) 2000-02-11 2002-12-11 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Identifizierung einer domäne in der familie der tumornekrose-faktor rezeptoren, die die anordnung des rezeptors vor der ligandbindung und sein funktion vermittelt
TR200300478T2 (tr) 2000-10-13 2004-10-21 Biogen Inc. Hümanize antiLT-ß-R antikorları
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
NZ550185A (en) 2002-03-04 2008-10-31 Merck Hdac Res Llc Methods of inducing terminal differentiation Methods of inducing terminal differentiation
EP1539793A4 (de) 2002-07-01 2006-02-01 HUMANISIERTE ANTI-LYMPHOTOIN-BETA-REZEPTOR-ANTIKöRPER
CA2496048A1 (en) * 2002-08-14 2004-02-26 Erasmus University Medical Center Rotterdam Use of murine genomic regions identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer
WO2004016317A1 (en) * 2002-08-14 2004-02-26 Erasmus University Medical Center Rotterdam Use of murine genomic regions identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
BRPI0509201A (pt) 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
CN101073665B (zh) * 2006-05-17 2014-11-26 上海复旦张江生物医药股份有限公司 淋巴毒素在制备增加化疗药物敏感性的药物中的应用
SG178002A1 (en) 2006-10-20 2012-02-28 Biogen Idec Inc Treatment of demyelinating disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747023A (en) * 1994-07-01 1998-05-05 Genentech, Inc. Cancer therapy using lymphotoxin
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
CA2229449A1 (en) * 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Novel receptor protein and its use

Also Published As

Publication number Publication date
ES2211035T3 (es) 2004-07-01
PT1051187E (pt) 2004-03-31
KR100622960B1 (ko) 2006-09-12
IS5570A (is) 2000-07-21
IL137489A0 (en) 2001-07-24
CZ20002751A3 (cs) 2000-12-13
AU2348899A (en) 1999-08-16
SK285725B6 (sk) 2007-07-06
CN1287853C (zh) 2006-12-06
JP2010235621A (ja) 2010-10-21
EP1051187B1 (de) 2003-11-12
EE05235B1 (et) 2009-12-15
PL203279B1 (pl) 2009-09-30
DE69912743T2 (de) 2004-09-23
NO20003848L (no) 2000-10-02
WO1999038525A1 (en) 1999-08-05
CZ301026B6 (cs) 2009-10-14
NZ506529A (en) 2002-12-20
EA003862B1 (ru) 2003-10-30
EA200000798A1 (ru) 2001-02-26
HUP0102363A2 (hu) 2001-10-28
PL342063A1 (en) 2001-05-21
NO328116B1 (no) 2009-12-14
SK11302000A3 (sk) 2001-01-18
ATE253930T1 (de) 2003-11-15
HU226044B1 (en) 2008-03-28
BR9908214A (pt) 2000-11-28
NO20003848D0 (no) 2000-07-27
JP4713733B2 (ja) 2011-06-29
CN1289252A (zh) 2001-03-28
HK1029944A1 (en) 2001-04-20
EP1051187A1 (de) 2000-11-15
EP1051187B9 (de) 2004-08-11
IS2254B (is) 2007-06-15
TR200101693T2 (tr) 2002-06-21
CA2319698A1 (en) 1999-08-05
DE69912743D1 (de) 2003-12-18
IL137489A (en) 2010-05-31
KR20010040497A (ko) 2001-05-15
AU752710B2 (en) 2002-09-26
TR200002203T2 (tr) 2000-12-21
JP2002501902A (ja) 2002-01-22
HUP0102363A3 (en) 2004-04-28
EE200000446A (et) 2001-08-15

Similar Documents

Publication Publication Date Title
BR0312785A (pt) Tratamento de desordens relacionadas a tnf(alfa)
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
IS5728A (is) Nýir hirflar af dípeptidýl peptíðasa IV
ES2153337T1 (es) Inhibidores de raf-quinasa.
DK1206474T3 (da) Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
TR200003514T2 (tr) Pirol ikame edilmiş 2-indolinon protein kinaz inhibitörleri
ID26620A (id) Penghambatan kinase raf yang menggunakan urea-urea heterosiklik yang disubstitusi
TR200003206T2 (tr) İndol türevleri ve patolojik hücre çoğalmasının neden olduğu habis hastalıklar ve diğer hastalıkların tedavisinde kullanımları.
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
TR200103216T2 (tr) Pirimidinon bileşimleri
CY1107531T1 (el) Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου
DK1325011T3 (da) Fremgangsmåder og forbindelser til behandling af proliferative sygdomme
EA200400235A1 (ru) Комбинированная терапия для лечения рака
PT1051187E (pt) Tratamento de linfomas foliculares usando inibidores da via da linfotoxina (lt)
DK1185279T3 (da) Midler til behandling af maligne sygdomme ved anvendelse af proteinet YB-1
UY26265A1 (es) Compuestos calciolíticos
EA200200853A1 (ru) Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака
DE69930844D1 (de) Inhibitoren von mycobakterien
DK1455770T3 (da) Anvendelse af norepinephringenoptagelsesinhibitorer til behandling af tic lidelser
TR200003084T2 (tr) Paroxetine askorbat
DK1393277T3 (da) Anvendelse af NF-Kappa-B inhibitorer til behandling af öjentörhedslidelser
AU2013204147B2 (en) Treatment of TNFalpha related disorders
ECSP003440A (es) Nuevos compuestos de pirimidinona y procedimiento